This page shows the latest Ardelyx news and features for those working in and with pharma, biotech and healthcare.
Drug hit primary and all secondary endpoints. California biotech Ardelyx has a second positive trial for its lead drug tenapanor in chronic kidney disease (CKD), as it waits for an FDA ... Shares in Ardelyx rocketed 72% on the back of the new study on
Now, Ardelyx is paying $25m back to AZ in order to reclaim rights to the programme and "accelerate the clinical development path" for drug. ... Ardelyx still has a $200m partnership in place with Sanofi for NaP2b inhibitors used in the treatment of
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
201. Ardelyx (formerly Nteryx) / Sanofi. Licence. 1. NaP2b inhibitor programme for ESRD.
In keeping with the trend seen with many other biotech deals, Ardelyx has an option to co-promote the product in the US. ... 572. Ardelyx / AstraZeneca. Licence. RDX5791 for end stage renal and chronic kidney disease and IBS-C (phase II).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Executive VP of Infinity Pharmaceuticals joins the team. Ardelyx has appointed William Bertrand Jr to its board of directors. ... Ardelyx is a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases.
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.